Picture of Anteris Technologies Global logo

AVR Anteris Technologies Global Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapNeutral

Momentum

Relative Strength (%)
1m-51.24%
3m-45.04%
6mn/a
1yrn/a
Volume Change (%)
10d/3mn/a
Price vs... (%)
52w High-67.29%
50d MA-50.29%
200d MA-50.33%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-123.6%
Return on Equity-185.94%
Operating Margin-2932.89%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202531st Dec 2026
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2025 / 2026

Blurred out image of Anteris Technologies Global EPS forecast chart

Profile Summary

Anteris Technologies Global Corp. is a structural heart company engaged in discovering, developing and commercializing medical devices designed to improve the quality of life for patients with aortic stenosis. It is engaged in the research and development of its biomimetic technology (ADAPT, DurAVR Transcatheter Heart Valve (THV), ComASUR Transfemoral Delivery System) to address unmet medical needs in the treatment of aortic stenosis. The DurAVR THV, with its single piece, native-shaped biomimetic design is built to mimic the performance of a healthy aortic valve and to restore normal laminar (smooth) blood flow. This class of technology can be used to treat new aortic stenosis patients and to treat aortic stenosis patients with failed valves (valve-in-valve). ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. ComASUR is its balloon-expandable delivery system.

Directors

    Last Annual
    December 31st, 2024
    Last Interim
    December 31st, 2024
    Incorporated
    January 29th, 2024
    Public Since
    December 13th, 2024
    No. of Shareholders
    3,669
    No. of Employees
    136
    Sector
    Healthcare Equipment & Supplies
    Industry
    Healthcare
    Exchange
    us flag iconNASDAQ Global Market
    Shares in Issue
    36,023,796

    AVR Share Price Performance

    Similar to AVR

    Picture of 908 Devices logo

    908 Devices

    us flag iconNASDAQ Global Market

    Picture of Alpha Teknova logo

    Alpha Teknova

    us flag iconNASDAQ Global Market

    Picture of AtriCure logo

    AtriCure

    us flag iconNASDAQ Global Market

    Picture of Beta Bionics logo

    Beta Bionics

    us flag iconNASDAQ Global Market

    Picture of Brainsway logo

    Brainsway

    us flag iconNASDAQ Global Market

    FAQ